Table 2 Identified literature overview
From: Health-related quality of life questionnaires in lung cancer trials: a systematic literature review
Author (Year) | Study, Phase tumor type stadium | Treatment outline | HRQoL endpoints | QoL outcome | QoL instruments |
|---|---|---|---|---|---|
Agteresch HJ et al. (2002) [7] | Clinical trial NSCLC IIIB/IV | Adenosine 5'-Triphosphate (ATP) vs. non | secondary | No change in appetite and body comparison in the ATP group. Control group lost weight and appetite. | Rotterdam Symptom Checklist (RSCL) |
Baka S et al. (2005) [8] | Clinical trial, II NSCLC IIIB/IV | Comparison of two different treatment schedules for Gemcitabine | primary | Significant improvement in performance from baseline, no sign. difference between treatment schedules. | Subset Scale from the EORTC QLQ-C30 and LC13, Karnofsky performance scale |
Belani C et al. (2006) [9] | Clinical trial, III NSCLC IIIB/IV | Comparison of two Docetaxel-platinum regimens with Vinorelbine/Cisplatin | primary | Patients treated with Docetaxel-containing regimen had better QoL and relieved symptoms. | LCSS, EQ-5D |
Bezjak A et al. (2008) [10] | Clinical trial, III NSCLC IB/II | Adjuvant chemotherapy (Cisplatin and Vinorelbine vs. non) | secondary | After chemotherapy QoL returned to baseline by 9 months compared to 3 months in the control group. | EORTC QLQ-C30 |
Bezjak A et al. (2006) [11] | Clinical trial, III NSCLC advanced | Erlotinib vs. placebo after prior chemotherapy | secondary | Sign. Improvement in physical and global QoL, dypnea, cough, pain, emotional functioning, deterioration in sore mouth and hairloss compared to baseline. | EORTC QLQ-C30,-LC13 |
Bianco V et al. (2001) [12] | Clinical trial NSCLC IIIB/IV | Gemcitabine as single agent therapy in advanced NSCLC in elderly patients (>65) | primary | Improvement in QoL, reduction of symptoms. | Spitzer-Index, Instrumental Activities of Daily Living Scale (IADL), EORTC QLQ-C30,-LC13 |
Booton R et al. (2006) [13] | Clinical trial, III NSCLC III/IV | Docetaxel/Carboplatin vs. Mitomycin C/Cisplatin/Vinblastine vs. Ifosfamide/Cisplatin | secondary | No superiority of one regimen. | Hospital Anxiety and Depression Scale (HADS), EORTC QLQ-C30,-LC13 |
Bozcuk H et al. (2006) [14] | Clinical trial NSCLC IIIB/IV | Examining determinants of a QoL improvement with chemotherapy in patients with advanced NSCLC. | primary | Age, baseline QoL and chemotherapy administration influence the degree of change in QoL. | EORTC QLQ-C30 |
Brown J et al. (2005) [15] | Clinical trial NSCLC IV | Supportive care with vs. without additional chemotherapy | primary | No sign. difference in QoL. | EORTC QLQ-C30,-LC17 |
Cella D et al. (2005) [16] | Clinical trial, II NSCLC advanced | Comparison of two different treatment dosages Gefitinib in heavily pretreated patients | primary and secondary | QoL improvements were correlated with tumor response. | FACT-L |
Chen M.-L. (2008) [17] | Clinical trial NSCLC IIIB/IV, SCLC | Examining the impact of sleep disturbance of lung cancer patients undergoing chemotherapy on their QoL | primary | Sign. impact on the cognitive function and functional status. | HADS, Pittsburgh Sleep Quality Index (PSQI), Brief Pain Inventory (BPI), EORTC QLQ-C30,-LC13 |
Dancey J et al. (2004) [18] | Clinical trial, III NSCLC IIIB/IV | Docetaxel second-line vs. Best Supportive Care (BSC) | secondary | A trend towards less deterioration in QoL compared to BSC | LCSS EORTC QLQ-C30,-LC13 |
de Marinis F et al. (2008) [19] | Clinical trial, III NSCLC III/IV | Pemetrexed vs. Docetaxel | secondary | Positive response on chemotherapy correlates with symptom improvement. | LCSS |
Gelibter A et al. (2005) [20] | “Compassionate-Use” NSCLC III/IV | Gefitinib | primary | Improvements in fatigue, insomnia, and pain, deterioration in sore mouth, chest-pain, diarrhea. | EORTC QLQ-C30,-LC13 |
Gridelli C et al. (2003) [21] | Clinical trial, III NSCLC IIIB/IV | Gemcitabine/Vinorelbine vs. Gemcitabine/Cisplatin vs. Vinorelbine/Cisplatin | primary | Global QoL is not improved with Gemcitabine/Vinorelbine. | EORTC QLQ-C30,-LC13 |
Grønberg BH et al. (2009) [22] | Clinical trial, III NSCLC IIIB/IV | First-line Pemetrexed/Carboplatin vs. Gemcitabine/Carboplatin | primary | Pemetrexed/Carboplatin provides similar HRQoL with less need for supportive care. | EORTC QLQ-C30,-LC13 |
Helbekkmo N et al. (2009) [23] | Clinical trial, III NSCLC IIIB/IV | Carboplatin Chatelut AUC/Vinorelbine or Carboplatin/Gemcitabine in patients with a performance status (PS) 2 compared to patients with PS 0/1 | primary | PS 2 patients had a more profound improvement of global HRQoL. | EORTC QLQ-C30,-LC13 |
Hensing TA et al. (2003) [24] | Clinical trial, III NSCLC IIIB/IV | 4 cycles of Carboplatin/Paclitaxel or until disease progression in patients younger than age 70 compared to those aged 70 years and older | primary | No difference in QoL outcomes. | FACT-L |
LeCaer H et al. (2005) [25] | Clinical trial, II NSCLC IIIB/IV | Docetaxel monotherapy in elderly patients | primary | QoL remained stable during treatment. | Spitzer-Index EORTC QLQ-C30,-LC13 |
Leighl NB et al. (2005) [26] | Clinical trial, III NSCLC IIIB/IV | Paclitaxel/Carboplatin with or without BMS-275291 | secondary | No detailed results presented. | EORTC QLQ-C30,-LC13 |
Lilenbaum R et al. (2007) [27] | Clinical trial, II NSCLC IIIB/IV | Erlotinib vs. Paclitaxel/Carboplatin in patients with a performance status (PS) of 2 | secondary | No sign. differences. | EORTC QLQ-LC13 |
Maione P et al. (2005) [28] | Clinical trial, III NSCLC IIIB/IV | The prediction of pretreated QoL on the survival of elderly NSCLC patients treated with chemotherapy | primary | Pretreatments global QoL has a sign. prognostic value for survival of elderly patients with advanced NSCLC treated with chemotherapy. | EORTC QLQ-C30,-LC13 |
McQuellon R P et al. (2002) [29] | Clinical trial, III NSCLC, SCLC | Megestrol Acetate vs. placebo in patients undergoing radiation therapy | primary | No sign. difference in overall QoL. | FACT-General, FACT-L |
Mohan A et al. (2008) [30] | QoL-study NSCLC III/IV | Cisplatin/Etoposide | primary | Sign. improvement in cough, shortness of breath, pain but not in QoL. | WHOQOL-BREF, Hindi |
Moinpour CM et al. (2002) [31] | Clinical trial, III NSCLC IIIB/IV | Cisplatin/Vinorelbine vs. Carboplatin/Paclitaxel | secondary | No sign. difference in QoL. | FACT-L |
Morita S et al. (2003) [32] | Clinical trial, III NSCLC IIIB/IV | Cisplatin/Irinotecan vs. Cisplatin/Vindesine vs. Irinotecan | secondary | Clinical parameters have a sign. effect on QoL in patients undergoing chemotherapy. | QoL questionnaire for cancer patients treated with anti-cancer drugs (QOL-ACD) |
Movsas B et al. (2005) [33] | Clinical trial NSCLC II/IIIA/B | Paclitaxel/Carboplatin with or without Amifostine | secondary | QoL was not sign. different between the arms. | EORTC QLQ-C30,-LC13 |
Mu XL et al. (2004) [34] | “Compassionate-Use” NSCLC III/IV | Gefitinib | primary | Symptom relief and improvement in QoL. | EORTC QLQ-C30,-LC13 |
Natale RB (2004) [35] | Clinical trial, II NSCLC advanced | Different treatment dosages Gefitinib | secondary | Improvements in symptoms and QoL. | FACT-L |
O’Brian MER et al. (2006) [36] | Clinical trialSCLC | Best Supportive Care with or without Topotecan in patients with relapsed SCLC | secondary | Slower QoL deterioration and greater symptom control. | Patient self assessment similar to the LCSS, EQ-5D |
Paccagnella A et al. (2004) [37] | Clinical trial, III NSCLC IIIB/IV | Mitomycin/Vinblastine/Cisplatin vs. Mitomycin/Vinblastine/Carboplatin | primary | Spitzer’s questionnaire showed an improved QoL index for Carboplatin. | Spitzer-Index, EORTC QLQ-C30,-LC13 |
Pijls-Johannesma M et al. (2009) [38] | QoL-study NSCLC I – III, SCLC | Radiotherapy with or without chemotherapy | primary | Overall QoL increases back to baseline within 3 months. | EORTC QLQ-C30,-LC13 |
Reck M et al. (2006) [39] | Clinical trial, III SCLC | Paclitaxel/Carboplatin/Etoposide phosphate vs. Carboplatin/Etoposide phosphate/Vincristine | primary | Paclitaxel-containing regimen sign. improved QoL parameters like global overall QoL. | EORTC QLQ-C30 |
Sarna L et al. (2008) [40] | Clinical trial, III NSCLC II/III | Paclitaxel/Carboplatin with or without Amifostin | primary | QoL was not sign. different between the arms. | EORTC QLQ-C30,-LC13 |
Schumacher A et al. (2003) [41] | Clinical trial, III NSCLC III | Cisplatin/Etoposide followed by either surgery before radiotherapy or radio-chemotherapy before surgery | primary | On QoL no sign. effect was found in or between the two treatments. | EORTC QLQ-C30,-LC13 |
Sekine I et al. (2009) [42] | Clinical trial, III NSCLC IIIB/IV | Gefitinib vs. Docetaxel | secondary | Gefitinib improved aspects of QoL over Docetaxel. | FACT-L |
Sirisinha T et al. (2005) [43] | N/A NSCLC II-IV | Docetaxel after failure with platinum-based chemotherapy | secondary | No negative impact on overall QoL. | FACT-L |
Thatcher N et al. (2005) [44] | Clinical trial SCLC | Ifosfamide/Carboplatin/Etoposid/Vincristine vs. standard chemotherapy | primary | No sign. differences regarding QoL. | Rotterdam Symptom Checklist, HADS, EORTC QLQ-C30,-LC13 |
Tian JH et al. (2010) [45] | Clinical trial NSCLC IIIB/IV | Chemotherapy vs. “Feiji Recipe” vs. Chemotherapy/“Feiji Recipe” | primary | "Feiji Recipe" alone or in combination might partially improve QoL. | EORTC QLQ-C30 |
Vilmar A et al. (2010) [46] | Clinical trial, III NSCLC III/IV | Chemotherapy; Determination of biomarker ERCC1 | primary | QoL deteriorated sign. among survival-favourable ERCC1-neg. patients | EORTC QLQ-C30,-LC13 |
von Plessen C et al. (2006) [47] | Clinical trial NSCLC IIIB/IV | Optimal duration of palliative Carboplatin with Vinorelbine treatment | primary | No sign. differences between the arms. | EORTC QLQ-C30,-LC13 |
Wu WY et al. (2006) [48] | QoL-study NSCLC IIIB/IV | Gemcitabine/Cisplatin with or without Shenfu Injektion | primary | Shengfu Injektion could improve QoL in patients with Gemcitabine/Cisplatin treatment. | Functional Living Index-Cancer, EORTC QLQ-C30 |
Zhang XT et al. (2005) [49] | “Compassionate-Use” NSCLC III/IV | Gefitinib | primary | Symptom relief and improvement in QoL. | EORTC QLQ-C30,-LC13 |